dc.contributor.author
Ghadjar, Pirus
dc.contributor.author
Aebersold, Daniel M.
dc.contributor.author
Albrecht, Clemens
dc.contributor.author
Böhmer, Dirk
dc.contributor.author
Flentje, Michael
dc.contributor.author
Ganswindt, Ute
dc.contributor.author
Höcht, Stefan
dc.contributor.author
Hölscher, Tobias
dc.contributor.author
Müller, Arndt-Christian
dc.contributor.author
Niehoff, Peter
dc.contributor.author
Pinkawa, Michael
dc.contributor.author
Sedlmayer, Felix
dc.contributor.author
Zips, Daniel
dc.contributor.author
Wiegel, Thomas
dc.contributor.author
Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and The Working Party Radiation Oncology of the German Cancer Society (DKG-ARO)
dc.date.accessioned
2022-09-21T12:30:16Z
dc.date.available
2022-09-21T12:30:16Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/36411
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-36127
dc.description.abstract
Aim: To provide an overview on the available treatments to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer.
Methods: The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published and assessed the validity of the information on efficacy and treatment-related toxicity.
Results: Eight randomized controlled trials and one meta-analysis were identified. Two randomized trials demonstrated that prophylactic radiation therapy (RT) using 1 × 10 Gy or 2 × 6 Gy significantly reduced the rate of gynecomastia but not breast pain, as compared to observation. A randomized dose-finding trial identified the daily dose of 20 mg tamoxifen (TMX) as the most effective prophylactic dose and another randomized trial described that daily TMX use was superior to weekly use. Another randomized trial showed that prophylactic daily TMX is more effective than TMX given at the onset of gynecomastia. Two other randomized trials described that TMX was clearly superior to anastrozole in reducing the risk for gynecomastia and/or breast pain. One comparative randomized trial between prophylactic RT using 1 × 12 Gy and TMX concluded that prophylactic TMX is more effective compared to prophylactic RT and furthermore that TMX appears to be more effective to treat gynecomastia and/or breast pain when symptoms are already present. A meta-analysis confirmed that both prophylactic RT and TMX can reduce the risk of gynecomastia and/or breast pain with TMX being more effective; however, the rate of side effects after TMX including dizziness and hot flushes might be higher than after RT and must be taken into account. Less is known regarding the comparative effectiveness of different radiation fractionation schedules and more modern RT techniques.
Conclusions: Prophylactic RT as well as daily TMX can significantly reduce the incidence of gynecomastia and/or breast pain. TMX appears to be an effective alternative to RT also as a therapeutic treatment in the presence of gynecomastia but its side effects and off-label use must be considered.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Gynecomastia
en
dc.subject
Prostate cancer
en
dc.subject
Antiandrogen therapy
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer
dc.type
Wissenschaftlicher Artikel
dc.title.subtitle
Statement from the DEGRO working group prostate cancer
dcterms.bibliographicCitation.doi
10.1007/s00066-020-01598-9
dcterms.bibliographicCitation.journaltitle
Strahlentherapie und Onkologie
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
589
dcterms.bibliographicCitation.pageend
597
dcterms.bibliographicCitation.volume
196
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
32166452
dcterms.isPartOf.issn
0179-7158
dcterms.isPartOf.eissn
1439-099X